AstraZeneca AB (quality control testing, packaging (primary and secondary), batch release; quality control testing)

The drug is indicated for adult patients with estrogen receptor (ER)-positive and HER2-negative locally advanced or metastatic breast cancer. It is used in combination with fulvestrant if certain genetic alterations (alterations in the PIK3CA, AKT1, or PTEN genes) are detected in the tumor after previous treatment has failed.

Dosage form: tablets, film-coated

ATC: L01EX27

The drug is prescribed to adult patients with estrogen receptor (ER)-positive and HER2-negative locally advanced or metastatic breast cancer. It is used in combination with fulvestrant if certain genetic alterations (alterations in the PIK3CA, AKT1, or PTEN genes) are detected in the tumor after the cancer has begun to progress during or after endocrine therapy.

Dosage form: tablets, film-coated

ATC: L01EX27